Increasing choice to treat obesity

Abstract

Get full access to this article

View all access options for this article.

References

Bray GA Risks of obesity. Endocrinol Metab Clin N Am 2003;32:787-804.

Williams KV , Kelley DE Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000 ;2:121-9.

Norris SL , Zhang X. , Avenell A. et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. A meta-analysis. Arch Intern Med 2004;164:1395-404.

Di Marzo V. , Bifulco M. , De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.

Van Gaal LF , Rissanen AM , Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389-97.

Despres JP , Golay A. , Sjostrom L. et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 ;353:2121-34.

Scheen AJ Rimonabant in overweight and obese type 2 diabetes. American Diabetes Association. 65th annual Scientific Sessions: Abstract 7-LB. Presented 12 June 2005.